@article {Chan3339作者={陈阿比和Alexa沃特和詹姆斯贵港市希(merrill Lynch)和安德里亚·施奈德和丹尼尔Sandsmark雷蒙Diaz-Arrastia}, title ={关系白质Hyperintensities轴突损伤和血液标志物和白质完整性(好- 7.002)},体积={100}={17补充2},elocation-id = {3339} = {2023}, doi = {10.1212 / WNL。出版商0000000000203197}= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:评估白质hyperintensities之间的关系(负责人),扩散张量成首页像(DTI)和blood-based生物标志物在创伤性脑损伤(TBI)患者。背景:研究负责人是一个常见neuroradiologic发现创伤性脑损伤的患者;然而,他们的协会与其他创伤性脑损伤的生物标志物在很大程度上是未知的。设计/方法:非穿刺性创伤性脑损伤的患者在24小时内注册入学。参与者进行了MRI在两周和血液收集第一天,第三天,具有抑制受损。延伸两周,6个月DTI数据预处理后,平均分数各向异性(FA)和平均扩散系数(MD)计算。负责人被计入juxtacortical、皮层下和室周的地区。血液处理使用Simoa HD-X Neuro4plex试验获得GFAP的浓度,NfL, UCH-L1。结果:100人与创伤性脑损伤包括(平均年龄38.3岁,76 \ %男,52 \ %黑色;格拉斯哥昏迷评分中位数得分15(差:14 {\ textendash} 15))。这些人,39 \ % neuroradiologist负责人确认。那些负责人的足总有显著降低(p = 0.007)和更高的MD (p = 0.04)相比没有负责人。 More specifically, Spearman{\textquoteright}s correlations demonstrated significant relationships (p\<0.05) between MD and number of WMH in subcortical areas (r=0.28) and between FA and number of WMH in juxtacortical (r=-0.34), subcortical (r=-0.42), and periventricular areas (r=-0.34). Logistic regression, controlling for age, revealed no significant relationships between WMH presence and any blood-biomarkers of interest. Zero inflated negative binomial regressions, controlling for age, also revealed no significant relationships between number of WMH in juxtacortical regions and GFAP or NfL. There was a significant relationship for Day 1 UCH-L1 where, for every one unit increase, there is 1.36 times more WMH (p=0.023, 95\%CI: 1.04, 1.77).Conclusions: WMH are associated with more severe and widespread white matter damage as measured by DTI. Blood biomarkers may also provide both complementary and distinctive information regarding physiological processes following TBI.Disclosure: Miss Chan has nothing to disclose. Alexa Walter has nothing to disclose. Dr. Gugger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ceribell. The institution of Dr. Gugger has received research support from American Epilepsy Society. Cillian Lynch has nothing to disclose. Dr. Schneider has nothing to disclose. The institution of Dr. Sandsmark has received research support from NINDS. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ischemix, Inc. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pinteon Therapeutics. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BrainBox, LLC. Dr. Diaz-Arrastia has received stock or an ownership interest from BrainBox, LLC. Dr. Diaz-Arrastia has received stock or an ownership interest from NovaSignal . Dr. Diaz-Arrastia has received stock or an ownership interest from Nia Therpeutics. The institution of Dr. Diaz-Arrastia has received research support from National Institutes of Health. The institution of Dr. Diaz-Arrastia has received research support from Department of Defense.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/100/17_Supplement_2/3339}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }